1. Home
  2. LEGN vs SPXC Comparison

LEGN vs SPXC Comparison

Compare LEGN & SPXC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LEGN
  • SPXC
  • Stock Information
  • Founded
  • LEGN 2014
  • SPXC 1912
  • Country
  • LEGN United States
  • SPXC United States
  • Employees
  • LEGN N/A
  • SPXC N/A
  • Industry
  • LEGN Biotechnology: Pharmaceutical Preparations
  • SPXC Industrial Machinery/Components
  • Sector
  • LEGN Health Care
  • SPXC Industrials
  • Exchange
  • LEGN Nasdaq
  • SPXC Nasdaq
  • Market Cap
  • LEGN 9.1B
  • SPXC 7.3B
  • IPO Year
  • LEGN 2020
  • SPXC N/A
  • Fundamental
  • Price
  • LEGN $38.19
  • SPXC $163.11
  • Analyst Decision
  • LEGN Strong Buy
  • SPXC Hold
  • Analyst Count
  • LEGN 13
  • SPXC 2
  • Target Price
  • LEGN $81.46
  • SPXC $142.00
  • AVG Volume (30 Days)
  • LEGN 1.6M
  • SPXC 268.1K
  • Earning Date
  • LEGN 11-12-2024
  • SPXC 10-30-2024
  • Dividend Yield
  • LEGN N/A
  • SPXC N/A
  • EPS Growth
  • LEGN N/A
  • SPXC 449.97
  • EPS
  • LEGN N/A
  • SPXC 3.72
  • Revenue
  • LEGN $520,183,000.00
  • SPXC $1,919,600,000.00
  • Revenue This Year
  • LEGN $110.04
  • SPXC $16.18
  • Revenue Next Year
  • LEGN $77.16
  • SPXC $6.43
  • P/E Ratio
  • LEGN N/A
  • SPXC $43.35
  • Revenue Growth
  • LEGN 122.96
  • SPXC 12.84
  • 52 Week Low
  • LEGN $38.02
  • SPXC $83.98
  • 52 Week High
  • LEGN $70.13
  • SPXC $173.30
  • Technical
  • Relative Strength Index (RSI)
  • LEGN 29.40
  • SPXC 52.53
  • Support Level
  • LEGN $38.94
  • SPXC $162.64
  • Resistance Level
  • LEGN $41.87
  • SPXC $170.28
  • Average True Range (ATR)
  • LEGN 2.20
  • SPXC 6.00
  • MACD
  • LEGN -0.30
  • SPXC 0.75
  • Stochastic Oscillator
  • LEGN 1.74
  • SPXC 73.16

About LEGN Legend Biotech Corporation

Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.

About SPXC SPX Technologies Inc.

SPX Technologies Inc supplies engineered heating, ventilation, and air conditioning, or HVAC, products, as well as detection and measurement technologies and power equipment. The company through two reportable segments. The HVAC segment which generates the majority of the revenue for the company, designs, manufactures, installs, and services cooling products, as well as heating and ventilation products. The detection and measurement technologies segment designs, manufactures, and installs underground pipe and cable locators and inspection equipment, bus-fare collection systems, and others. Geographically, the company generates majority of its revenue in the United States and rest from China, United Kingdom and other regions.

Share on Social Networks: